| name | endo-paget-hearing-loss-prevention |
| description | Suggests treatment with a potent bisphosphonate to prevent worsening of a hearing deficit in patients with Paget's disease involving the temporal bone. Triggers include detected or suspected hearing loss thought to be related to Paget's disease. |
Use potent bisphosphonate to prevent hearing loss worsening
STEP 1 — Gather Information
Collect history of hearing loss (onset, laterality, symptoms), perform audiometry, obtain plain radiographs of skull/temporal bone, order radionuclide bone scan to assess temporal bone involvement, and measure serum total alkaline phosphatase (ALP) or specific bone turnover markers (P1NP, CTx).
STEP 2 — Rule In / Rule Out
Rule in Paget’s-related hearing loss if hearing loss is present AND imaging/bone scan shows temporal bone uptake AND serum ALP or marker is elevated; rule out if hearing loss is isolated, bilateral high-frequency loss suggestive of presbycusis, or temporal bone shows no increased uptake.
STEP 3 — Classify or Stratify
Stratify by disease activity: active (elevated ALP/marker) vs inactive (normal markers) in the setting of confirmed temporal bone Paget’s.
STEP 4 — Decide
If active Paget’s disease of temporal bone with hearing loss, initiate potent bisphosphonate (e.g., intravenous zoledronate 5 mg over 15 minutes); if inactive, consider monitoring hearing and markers annually without bisphosphonate unless progression occurs.
Clinical Guardrails / Mimics / Pitfalls
Do not treat with bisphosphonate in patients with eGFR <35 mL/min, uncorrected vitamin D deficiency, or hypocalcemia; do not attribute hearing loss solely to presbycusis without evaluating for Paget’s involvement; do not use less potent oral bisphosphonates when IV zoledronate is available and indicated; do not delay treatment if hearing loss is progressing.
Concrete Clinical Example
A 70‑year‑old woman with known pelvic Paget’s reports worsening low‑frequency hearing in the left ear; audiometry shows a conductive component, serum ALP is 2× upper limit, and bone scan reveals focal increased uptake in the left temporal bone. She receives a single 5 mg IV zoledronate infusion; repeat audiometry at 6 months shows stabilization of hearing thresholds.
Source: Paget’s Disease of Bone: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, doi:10.1210/jc.2014-2910
